# Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy

> **NCT02891811** · PHASE2 · COMPLETED · sponsor: **Arbeitsgemeinschaft medikamentoese Tumortherapie** · enrollment: 124 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Thalidomide
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02891811
- **Lead sponsor:** Arbeitsgemeinschaft medikamentoese Tumortherapie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-10
- **Primary completion:** 2024-03-28
- **Final completion:** 2024-03-28
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2024-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02891811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02891811, "Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02891811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*